Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies.

Marozsan AJ, Ma D, Nagashima KA, Kennedy BJ, Kang YK, Arrigale RR, Donovan GP, Magargal WW, Maddon PJ, Olson WC.

J Infect Dis. 2012 Sep 1;206(5):706-13. doi: 10.1093/infdis/jis416. Epub 2012 Jun 25.

2.

Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors.

Berro R, Klasse PJ, Lascano D, Flegler A, Nagashima KA, Sanders RW, Sakmar TP, Hope TJ, Moore JP.

J Virol. 2011 Aug;85(16):8227-40. doi: 10.1128/JVI.00767-11. Epub 2011 Jun 15.

3.

Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542.

Jacobson JM, Israel RJ, Lowy I, Ostrow NA, Vassilatos LS, Barish M, Tran DN, Sullivan BM, Ketas TJ, O'Neill TJ, Nagashima KA, Huang W, Petropoulos CJ, Moore JP, Maddon PJ, Olson WC.

Antimicrob Agents Chemother. 2004 Feb;48(2):423-9.

4.

Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion.

Nagashima KA, Thompson DA, Rosenfield SI, Maddon PJ, Dragic T, Olson WC.

J Infect Dis. 2001 Apr 1;183(7):1121-5. Epub 2001 Mar 8.

PMID:
11237840
5.

Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.

Trkola A, Ketas TJ, Nagashima KA, Zhao L, Cilliers T, Morris L, Moore JP, Maddon PJ, Olson WC.

J Virol. 2001 Jan;75(2):579-88.

6.

Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5.

Olson WC, Rabut GE, Nagashima KA, Tran DN, Anselma DJ, Monard SP, Segal JP, Thompson DA, Kajumo F, Guo Y, Moore JP, Maddon PJ, Dragic T.

J Virol. 1999 May;73(5):4145-55.

7.

AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor.

Donzella GA, Schols D, Lin SW, Esté JA, Nagashima KA, Maddon PJ, Allaway GP, Sakmar TP, Henson G, De Clercq E, Moore JP.

Nat Med. 1998 Jan;4(1):72-7.

PMID:
9427609
8.

Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry.

Dragic T, Trkola A, Lin SW, Nagashima KA, Kajumo F, Zhao L, Olson WC, Wu L, Mackay CR, Allaway GP, Sakmar TP, Moore JP, Maddon PJ.

J Virol. 1998 Jan;72(1):279-85.

9.

Human immunodeficiency virus type 1 membrane fusion mediated by a laboratory-adapted strain and a primary isolate analyzed by resonance energy transfer.

Litwin V, Nagashima KA, Ryder AM, Chang CH, Carver JM, Olson WC, Alizon M, Hasel KW, Maddon PJ, Allaway GP.

J Virol. 1996 Sep;70(9):6437-41.

10.

HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.

Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, Paxton WA.

Nature. 1996 Jun 20;381(6584):667-73.

PMID:
8649512

Supplemental Content

Loading ...
Support Center